Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

Lilly partners with Indiana State Health Department for coronavirus testing

Experts maintain that testing can curb the outbreak

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

FDA green lights study of phage-based drug for resistant infections

Possible alternative to conventional antibiotics

Roche Basel Switzerland

FDA okays Roche’s COVID-19 diagnostic test

Increases capacity for testing as coronavirus cases grow

- PMLiVE

NHS increases COVID-19 testing capacity, FDA halts foreign inspections

New measures to tackle the novel coronavirus announced across the Atlantic

- PMLiVE

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Potential treatment for patient group with no FDA-approved drugs

- PMLiVE

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Trevena gets second go at FDA approval for pain drug

FDA sets review completion date of 7 August 2020

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links